PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells

Cancer Immunology Research

Volumn 3, Issue 12, 2015, Pages 1308-1315

  Mahoney, Kathleen M ^a   Sun, Heather ^b   Liao, Xiaoyun ^a   Hua, Ping ^a   Callea, Marcella ^b   Greenfield, Edward A ^a   Hodi, F Stephen ^a   Sharpe, Arlene H ^a   Signoretti, Sabina ^b   Rodig, Scott J ^a,b   Freeman, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; JANUS KINASE 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7G11; MONOCLONAL ANTIBODY 9A11; MONOCLONAL ANTIBODY SP142; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOMA CELL LINE; CELL MEMBRANE; CLASSICAL HODGKIN LYMPHOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GLYCOSYLATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OVARIAN CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; HISTOLOGY; IMMUNOLOGY; NEOPLASM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; STAINING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN STRUCTURE, TERTIARY; STAINING AND LABELING; TISSUE EMBEDDING;

EID: 84961249398     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0116     Document Type: Article

References (27)

1. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T-cell activation and cytokine production. J Immunol 2003; 170: 1257-66.
2. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
3. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. N Immunol 2001; 2: 261-8.
4. Yamazaki T, Akiba H, Iwai H,Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-45.
5. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immun 2007; 8: 239-45.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
7. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma. N Engl J Med 2013; 369: 134-144.
8. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013; 31: (suppl; abstr 9010).
9. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116: 3268-77.
10. Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74.
11. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101: 17174-9.
12. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PDL1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462-73.
13. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 3360-5.
14. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, GutierrezM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9.
15. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Translat Med 2012; 4: 127ra37.
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015; 372: 2018-28.
17. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, et al. Differential expression of PD-L1 between primary and metastatic sites in clear cell renal cell carcinoma. Cancer Immunol Res 2015; 3: 1158-64.
18. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
19. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-9.
20. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117: 2192-201.
21. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
22. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014; 32: 5s: (suppl; abstr 3002).
23. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5: 12189-202.
24. Ott PA, Hodi FS. The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: Opportunities for therapeutic intervention. Chin Clin Oncol 2013; 2: 7.
25. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology 2014; 28: 39-48.
26. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
27. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.